Matsuda et al. reported that everolimus, another structural analogue of rapamycin, ameliorates an IL10–/– colitis in mice probably as a result of decreasing the number of CD4+ T cells in the colonic mucosa and an associated reduction of IFN-γ production [30]. Here, CD4 is linked to colitis.